Sclerostin antibody treatment enhances metaphyseal bone healing in rats
暂无分享,去创建一个
[1] H. Genant,et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Guoyin Feng,et al. Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] Qing Chen,et al. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] Aaron Schindeler,et al. Bone remodeling during fracture repair: The cellular picture. , 2008, Seminars in cell & developmental biology.
[5] P. Kostenuik,et al. Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] P. Tengvall,et al. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. , 2008, Bone.
[7] David J J de Gorter,et al. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. , 2008, The Journal of bone and joint surgery. American volume.
[8] B. Alman,et al. Beta-Catenin Signaling Plays a Disparate Role in Different Phases of Fracture Repair: Implications for Therapy to Improve Bone Healing , 2007, PLoS medicine.
[9] P. Aspenberg,et al. Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: A randomized, double-blind radiostereometric study of 50 patients , 2007, Acta orthopaedica.
[10] R. Jilka,et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.
[11] P. Aspenberg,et al. Stimulation of implant fixation by parathyroid hormone (1–34)–A histomorphometric comparison of PMMA cement and stainless steel , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[12] M. Kneissel,et al. SOST is a target gene for PTH in bone. , 2005, Bone.
[13] P. ten Dijke,et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. , 2005, Cytokine & growth factor reviews.
[14] P. Aspenberg,et al. Systemic and local ibandronate enhance screw fixation , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[15] John A Latham,et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.
[16] P. Aspenberg,et al. Implant fixation enhanced by intermittent treatment with parathyroid hormone. , 2001, The Journal of bone and joint surgery. British volume.
[17] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[18] D. Galas,et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.
[19] P Nilsson,et al. Biomechanical characterization of osseointegration during healing: an experimental in vivo study in the rat. , 1997, Biomaterials.
[20] L Ryd,et al. Roentgen stereophotogrammetric analysis of prosthetic fixation in the hip and knee joint. , 1992, Clinical orthopaedics and related research.